Objectives: The ribosomal methylase Erm(41) confers inducible resistance to macrolides in Mycobacterium abscessus. The aim of this work was to systematically study and compare drug susceptibility to clarithromycin and azithromycin in M. abscessus and Mycobacterium chelonae clinical isolates with a particular focus on inducible drug resistance.
Introduction
Azithromycin is an orally administered azalide antimicrobial that is structurally related to macrolides. The serum concentration of azithromycin is lower than that of clarithromycin and erythromycin, 1 as azithromycin is rapidly removed from the circulation and extensively distributed to intracellular compartments. 1 -3 These unique pharmacokinetic properties of azithromycin allow for single daily dosages and intermittent treatment, 1 which can be beneficial for patient compliance, especially in the context of long-term regimens commonly required in mycobacterial infections.
Newer macrolides are considered key agents for the treatment of emerging infections caused by the closely related, rapidly growing mycobacterial species Mycobacterium abscessus and Mycobacterium chelonae. 4 In both species, acquired resistance to macrolides occurs through point mutations at positions 2058 or 2059 of the 23S rRNA (rrl) gene. 5, 6 In contrast to M. chelonae, M. abscessus harbours an inducible ribosomal methylase, Erm(41), which represents an additional intrinsic resistance mechanism against macrolides. Inducible resistance can be demonstrated either by pre-incubation for 3 days prior to drug susceptibility testing (DST) using subinhibitory macrolide concentrations between 0.125×and 0.5×MIC or by prolonging incubation up to 12 -14 days. 5, 7, 8 The subspecies designations within M. abscessus sensu lato, i.e. M. abscessus subsp. abscessus, M. abscessus subsp. bolletii and M. abscessus subsp. massiliense, are the subject of an ongoing taxonomic debate.
5,9 -13 M. abscessus subsp. abscessus and M. abscessus subsp. bolletii both usually carry an inducible erm(41) gene. 9 Recently, Bastian et al. 9 reported that a single nucleotide exchange, T28C (Trp-10 Arg), in erm(41) leads to a loss of methylase activity in M. abscessus subsp. abscessus, resulting in a phenotype that is naturally susceptible to macrolides. M. abscessus subsp. massiliense differs from M. abscessus subsp. abscessus and M. abscessus subsp. bolletii by an erm(41) that is dysfunctional due to two characteristic deletions (bases 64 -65 and 159 -432). 5, 13 Interestingly, two strains of M. abscessus subsp. massiliense with a functional erm(41) gene have been described recently.
14 Data comparing the efficacy of clarithromycin and azithromycin in rapidly growing mycobacteria (RGM) are scarce. Using the agar gradient diffusion method (Etest), Bastian et al. 9 reported that MICs of azithromycin for M. abscessus complex tend to be higher than those of clarithromycin. This is in accordance with an early report of Brown et al., 15 who observed higher MICs of azithromycin compared with clarithromycin for M. abscessus and M. chelonae using broth microdilution assays. However, the procedures used for species identification in the latter study at that time do not reflect current state-of-the-art taxonomy. 15 In contrast with these studies, Choi et al. 16 more recently reported that azithromycin is a weaker inducer of erm(41) gene expression than clarithromycin and should therefore be preferred in antibiotic therapy of M. abscessus infections. The aim of this work was to systematically evaluate the in vitro drug susceptibility of clarithromycin and azithromycin in M. abscessus and M. chelonae clinical isolates, with emphasis on inducible resistance.
Materials and methods

Strains
Clinical isolates of M. abscessus subsp. abscessus (n ¼ 21), M. abscessus subsp. bolletii (n¼16), M. abscessus subsp. massiliense (n¼10) and M. chelonae (n ¼ 22) were isolated from patient specimens between 2005 and 2013. Species identification was based on the sequences of the 16S rRNA, the rpoB and the erm(41) genes as described previously. 13, 17, 18 The erm(41) and rrl genotypes were determined by DNA sequence analysis as described previously. 19 In brief, the amplification primers used were MCLR 19F (5 ′ -GTAGCGAAATTCCTTGTCGG-3 ′ , E. coli rrl positions 1930 -1949) and MCLR 21R (5 ′ -TTCCCGCTTAGATGCTTTCAG-3 ′ , E. coli rrl positions 2765 -2745) for the rrl gene and erm41f2 (5 ′ -GACCGGGGCCTTCTT CGTGAT-3 ′ ) and erm41r2 (5 ′ -GACTTCCCCGCACCGATTCC-3 ′ ) for erm(41). The PCR conditions for the rrl PCR were 3 min at 958C, followed by 30 cycles at 958C for 60 s, 488C for 60 s and 728C for 120 s. The PCR conditions for erm(41) were 5 min at 958C, followed by 40 cycles at 948C for 30 s, 558C for 30 s and 728C for 60 s. Sequencing was performed using an Applied Biosystems 3130 Genetic Analyzer and BigDye Terminator Cycle Sequencing chemistry (Applied Biosystems, Carlsbad, CA, USA). The sequences were analysed using Lasergene SeqMan software (DNASTAR, Madison, WI, USA), the SmartGene database (SmartGene Zug, Switzerland) and the BLAST algorithm (http://blast.ncbi.nlm.nih.gov). To identify mutations in rrl, sequences were compared with the published M. abscessus subsp. abscessus genome (GenBank accession number NC_010397.1). The published sequences of M. abscessus subsp. abscessus strains ATCC 19977 (T28 sequevar, GenBank accession number FJ358483.1) and CR5701 (C28 sequevar, GenBank accession number HQ127366.1) were used as references for erm(41) analysis.
DST
DST was performed based on CLSI document M24-A2. 20 Antimicrobial compounds (Sigma-Aldrich, Buchs, Switzerland) were dissolved in DMSO (clarithromycin) or ethanol (azithromycin), filter sterilized, aliquotted into stock solutions of 5 g/L and stored at 2808C. Working solutions (256 mg/L, maximum final solvent concentration 5% v/v) were prepared by diluting thawed aliquots of the respective stock solutions in cation-adjusted Mueller -Hinton broth (CAMHB; Becton Dickinson, Allschwil, Switzerland) at pH 7.4. Two-fold serial dilutions of the working solutions were prepared in CAMHB using sterile 96-well microtitre plates (Greiner Bio-One, St Gallen, Switzerland). Visible precipitates indicative of decreased solubility of azithromycin or clarithromycin were not observed. Drug-free solutions were tested to exclude inhibitory activity of the solvents alone. For all antibiotics, a growth control containing no antibiotic and a negative control containing only CAMHB were included. Mycobacterium peregrinum ATCC 700686 was used as a quality control (QC) strain to test each new lot of antibiotic stock solutions. QC ranges were applied as recommended by the CLSI. 20 In addition, M. abscessus ATCC 19977 was tested with each new lot of antimicrobials as an internal QC.
For inoculum preparation, colonies were taken from fresh pure cultures grown on Luria-Bertani (LB) agar using sterile cotton swabs and transferred into glass vials containing 2 mL of sterile saline. Bacterial suspensions were adjusted to a turbidity equivalent to that of a ≥0. 5 McFarland standard and diluted in CAMHB to generate a final inoculum suspension of 1 -5×10 5 cfu/mL. Each inoculum solution was checked for purity and correct concentration by obtaining cfu counts of suitable dilutions plated on LB agar. After inoculation, microdilution plates were covered with adhesive seals and incubated at 378C for M. abscessus sensu lato or 308C for M. chelonae. Growth was assessed by visual inspection of the microtitre plates after 3, 7 and 12 days of incubation. In accordance with Nash et al.,
5 a clarithromycin MIC of .32 mg/L at day 12 was used as the criterion for inducible macrolide resistance. For pre-incubation experiments, MIC testing was repeated following 3 days of pre-incubation of liquid cultures in 0.25× MIC of clarithromycin and azithromycin, respectively. 5, 7, 8 Prior to MIC testing, pre-incubated liquid cultures were pelleted and washed twice using CAMHB to remove residual antibiotics. For all MIC determinations using pre-incubated isolates, sequencing of the erm(41) gene was performed before and after the 3 day pre-incubation period as well as at day 12 of MIC testing in order to exclude the simultaneous presence of mixed C28 and T28 populations or a potential selection of the T28 genotype.
Results
DST
Using the broth microdilution method based on the current CLSI recommendations, 20 we determined MIC ranges and median MICs of clarithromycin and azithromycin for a set of clinical RGM isolates: M. abscessus subsp. abscessus (T28 sequevars), n ¼ 21; M. abscessus subsp. bolletii, n ¼ 16; M. abscessus subsp. massiliense, n ¼ 10; and M. chelonae, n ¼ 22 (Table 1 ). The data show that the MICs of azithromycin were consistently higher than those of clarithromycin for all examined isolates. In strains carrying an inducible Erm(41) methylase, high median MICs of both clarithromycin and azithromycin were observed at day 7 (azithromycin .256 mg/L and clarithromycin 32 mg/L for M. abscessus subsp. abscessus T28 sequevars; azithromycin .256 mg/L and clarithromycin 128 mg/L for M. abscessus subsp. bolletii).
Assessment of inducible macrolide resistance
We additionally studied the effect of pre-incubation with macrolides on selected M. abscessus isolates. For M. abscessus subsp. abscessus ATCC 19977 and a clinical M. abscessus subsp. abscessus isolate [both erm(41) T28 sequevars], pre-incubation at subinhibitory concentrations of either clarithromycin or azithromycin resulted in a marked increase in the MICs of both compounds between days 3 and 12 (Figure 1a and b) . Inducible resistance was at least as pronounced against azithromycin as against clarithromycin in M. abscessus subsp. abscessus erm(41) T28 sequevars, regardless of pre-incubation (Figure 1a and b) . A similar but much less pronounced increase in MIC values was observed for the two M. abscessus subsp. abscessus erm(41) C28 sequevars, again regardless of pre-incubation (Figure 1c and d) . Azithromycin and clarithromycin MIC readings on day 12 were below or around 16 and 2 mg/L, respectively, and thus much lower than those for the two T28 sequevars (both .256 mg/L, Figure 1a and b) . Interestingly, the day 12 azithromycin values for the two C28 sequevars were clearly higher than the day 12 azithromycin MICs for clinical M. abscessus subsp. massiliense isolates, which carry a large deletion in the erm(41) gene (see Figure 1e) . A control clinical M. abscessus subsp. abscessus isolate carrying the rrl mutation A2058G showed clarithromycin and azithromycin MICs of .256 mg/L already on day 3, regardless of pre-incubation (Figure 1f) .
Effect of the medium composition on the MICs of clarithromycin and azithromycin
The two liquid media used for DST in the previous studies differ both in their composition and acidity. 9, 16 Bastian et al. 9 employed the widely used CAMHB (pH 7.4) medium, which contains beef extract, hydrolysed casein, starch and defined amounts of Ca 2+ and Mg 2+ . Choi et al. 16 used Middlebrook 7H9 medium, which is a complex liquid growth medium frequently used for the cultivation of mycobacteria. Middlebrook 7H9 has a lower pH (pH 6.8) and contains a large number of inorganic salts. Since macrolide activity is sensitive to pH, 1, 20 we hypothesized that the use of the different media may influence the MIC values. Clarithromycin MICs for M. abscessus subsp. abscessus ATCC 19977 on days 3, 7 and 12 were 4, 4 and 32 mg/L in Middlebrook 7H9 and 1, 8 and 256 mg/L in CAMHB, respectively. For the same strain, the observed azithromycin MICs were 8, 256 and .256 mg/L in Middlebrook 7H9 and 2, 64 and 256 mg/L in CAMHB, respectively. Azithromycin consistently showed an inducible resistance phenotype comparable to that of clarithromycin also at additional pH levels (pH 6.1 and 8.1) in both media (data not shown).
Discussion
Macrolides such as clarithromycin and azithromycin are important components of therapeutic regimens against infections caused by M. abscessus sensu lato and M. chelonae. Proper identification of M. abscessus isolates to the subspecies level is indispensable, since significant differences exist in natural resistance to macrolides due to a functional, dysfunctional or non-existent erm(41) gene. 5, 9 Recently, Bastian et al. 9 investigated a significant number of M. abscessus complex clinical isolates by phenotypic DST for clarithromycin and azithromycin and by sequencing of the erm(41) gene. These results indicated that MICs of azithromycin were generally higher than those of clarithromycin after 5 and 7 days of incubation. 9 In contrast, experiments conducted more recently by Choi et al. 16 in M. abscessus subsp. abscessus indicated that clarithromycin was a stronger inducer of erm(41), leading to higher mRNA expression and a more rapid increase in MICs during prolonged incubation compared with azithromycin.
In order to resolve these apparently conflicting results, we reanalysed the methodology used in the published studies and conducted additional experiments. We have identified significant methodological differences between the above-mentioned studies and the current CLSI guideline, which recommends broth microdilution in CAMHB for routine DST of RGM. 20 Bastian et al. 9 used a commercial broth microdilution method (with prolonged incubation for inducible macrolide resistance) for clarithromycin and the agar gradient diffusion method (Etest) for azithromycin to compare MIC ranges and mean MICs of the two drugs. Choi et al. 16 used pre-incubation and prolonged incubation in Middlebrook 7H9 medium (pH 6.8) to evaluate differences in inducible resistance between clarithromycin and azithromycin.
Our data using CAMHB (pH 7.4) and test conditions based on the CLSI guidelines show that the median MICs of azithromycin for M. abscessus sensu lato and M. chelonae are markedly higher 
,0. Comparative macrolide MICs for Mycobacterium abscessus 1561 JAC than those of clarithromycin. Inducible resistance was comparable or even slightly more pronounced for azithromycin than for clarithromycin in both M. abscessus subsp. abscessus erm(41) T28 sequevars and M. abscessus subsp. bolletii (Table 1) . We conducted additional experiments with pre-incubation followed by prolonged incubation using representative strains belonging to the M. abscessus complex and compared the results with those from our standard testing system (prolonged incubation alone). In contrast to the recent report of Choi et al., 16 our results do not show that clarithromycin triggers a more rapid or more pronounced erm(41)-related macrolide resistance than azithromycin in M. abscessus sensu lato. We observed a similar inducible resistance phenotype for both compounds, despite the generally higher MICs of azithromycin compared with clarithromycin (Table 1 and Figure 1 ). We hypothesized that differences in growth media, e.g. pH, might influence azithromycin activity, which might explain the different results by Choi et al. 16 However, additional experiments in Middlebrook 7H9 and standard CAMHB medium ruled out this possibility.
We also observed that M. abscessus subsp. abscessus erm(41) C28 sequevars showed increasing MIC levels during prolonged incubation with clarithromycin. This observation is supported by the previous finding that both T28 and C28 sequevars show a comparable increase in mRNA transcripts upon exposure to macrolides. 5 The MICs of clarithromycin and azithromycin did not increase to .32 mg/L at day 12 and thus were much lower than those for M. abscessus subsp. abscessus T28 sequevars. However, these MICs were clearly higher than the macrolide MICs for M. abscessus subsp. massiliense, which possesses an erm(41) with a large deletion ( Table 1) . These results suggest that the single amino acid exchange, Trp-10 Arg (T28C), does not completely abort Erm(41) functionality and that a deletion as found in M. abscessus subsp. massiliense is required to result in a completely dysfunctional gene product. However, since only two M. abscessus subsp. abscessus C28 sequevars were available to us, this observation will require further clarification on a larger set of such strains.
In conclusion, the median MICs of azithromycin were higher and increased at a similar rate during prolonged incubation compared with those of clarithromycin for clinical M. abscessus complex isolates. Variation of our standard test conditions with respect to pre-incubation, pH and medium did not support the notion that azithromycin is a weaker inducer of erm(41)-related macrolide resistance in M. abscessus sensu lato than clarithromycin. 16 Our data show that the single amino acid exchange Trp-10 Arg in erm(41) does not result in a complete loss of inducibility, although MICs of both macrolides after prolonged incubation remained well below those for erm(41) T28 sequevars. Our data further show that both clarithromycin and azithromycin may trigger inducible macrolide resistance in vitro and that caution is advisable when using either compound in vivo in the presence of a functional Erm(41) methylase.
